NVS vs PFE

For growth investors, Novartis AG (NVS) is the stronger pick with 6.

0% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Pfizer Inc. (PFE) offers the better valuation at 19. 4x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Novartis AG (NVS) a "Hold" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pfizer Inc.

(PFE) is the cheapest at 19. 4x versus Novartis AG at 20. 2x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +97.

8%, compared to -13. 2% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: NVS returned +180. 1% versus PFE's +30. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.

42β versus Pfizer Inc. 's 0. 54β — meaning PFE is approximately 28% more volatile than NVS relative to the S&P 500. On balance sheet safety, Pfizer Inc. (PFE) carries a lower debt/equity ratio of 78% versus 80% for Novartis AG — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novartis AG (NVS) is pulling ahead at 6.

0% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Novartis AG grew EPS 22. 5% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, NVS leads at 8. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novartis AG (NVS) is the more profitable company, earning 25.

6% net margin versus 12. 4% for Pfizer Inc. — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus 24. 7% for PFE. At the gross margin level — before operating expenses — NVS leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 8. 9x forward P/E versus 16. 6x for Novartis AG — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PFE: 3. 1% to $27. 27.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 6. 5%, versus 2. 8% for Novartis AG (NVS).

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 2. 8% yield, +180. 1% 10Y return). Both have compounded well over 10 years (NVS: +180. 1%, PFE: +30. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NVS is a large-cap quality compounder stock; PFE is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.